#Sweden #Gothenburg #Getinge #Cardiohelp II #ECLS therapy

Getinge's Q3 2026 Financial Highlights

In the recently released interim report for July to September 2026, Getinge has demonstrated remarkable performance, with organic growth in both order intake and sales. According to CEO Mattias Perjos, the company not only improved profitability but also generated substantial cash flow during this period.

Key metrics from the report indicate that sales growth was primarily propelled by the Acute Care Therapies sector. Performance within Surgical Workflows remained stable, driven largely by operating room equipment orders, affirming the sector's resilience. Additionally, the Life Science segment exhibited a mixed performance; while the Sterile Transfer category showed robust results, the WIS division—which incorporates capital-intensive products like washer-disinfectors—faced challenges due to ongoing low investment levels in the pharmaceutical sector.

The adjusted EBITA margin saw a marked improvement, rising to 15.1%. This positive shift was aided by tariff refunds amounting to SEK 45 million and favorable currency effects totaling roughly SEK 36 million. Even when these factors are set aside, the operational margin enhanced by more than one percentage point to an impressive 14.3%, reflecting the underlying strength of the business.

Perjos highlighted that the improved profitability was a result of a favorable product mix, adherence to pricing strategies, and enhancements in productivity. This combination laid the groundwork for strong cash flow, which also improved due to developments in working capital.

In a significant milestone during this quarter, Getinge initiated the launch of the Cardiohelp II platform, the next-generation Extended Circulatory Life Support (ECLS) therapy system. This new product has already received positive feedback from customers in CE-marked countries and Hong Kong. Furthermore, the company secured 510(k) clearance for a new Edi catheter, designed to assist premature infants as light as 500 to 1000 grams in their breathing efforts when used alongside Getinge's ventilators.

A notable innovation introduced in this quarter is the Torin Plan Optimizer, an artificial intelligence-driven tool aimed at enhancing resource management and making surgical workflows more predictable.

Perjos emphasized that Getinge's core strength lies in the dedication and collaboration of their global team with customers. He expressed gratitude for achieving all-time highs in both customer satisfaction and employee engagement, especially amid an unpredictable global environment. So far, these insights have led the company to maintain its projections for a 3-5% organic net sales growth for the entirety of 2026.

Key Data from July-September 2026

• - Net Sales: Up by 2.1% (from 9.5% in the previous year)
• - Order Intake: Increased by 2.6% (compared to 4.7% a year prior)
• - Adjusted Gross Profit: SEK 4,343 million (up from SEK 4,051 million)
• - Gross Margin: 51.4% (up from 49.2%)
• - Adjusted EBITA: SEK 1,278 million (up from SEK 1,079 million)
• - EBITA Margin: 15.1% (up from 13.1%)
• - Adjusted EPS: SEK 3.10 (from 2.42)
• - Free Cash Flow: SEK 1,302 million (compared to 793 million previously)

On October 21, a conference call will take place to discuss these results in detail, where CEO Mattias Perjos and CFO Agneta Palmér will shed further light on the numbers and the strategies moving forward. Interested parties are encouraged to register for the conference call to participate actively.

In conclusion, Getinge's performance for Q3 2026 paints a picture of a robust company that is navigating challenges effectively while focusing on innovation and maintaining high standards of customer satisfaction. As they look ahead to the remaining year and beyond, the outlook remains positive, with strategic initiatives underpinning growth aspirations.

For further press inquiries or more detailed financial information, please contact David Kördel, Head of Investor Relations at Getinge.